蛋白尿性肾病治疗动态──钙拮抗剂临床应用争议的初步探讨

来源 :国外医药(合成药 生化药 制剂分册) | 被引量 : 0次 | 上传用户:tanxiaoxi
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
蛋白尿为预测病人肾功能恶化的重要临床标志,有报道指出钙拮抗剂可望减少尿蛋白,晚近有作者对此提出异议,认为该类药物可导致肾脏自身调节功能失常及近球小管超负荷等不良反应而加重肾脏损害。据此,本文综述近年有关钙拮抗剂治疗蛋白尿性肾病的诸多观点,以供借鉴。 Proteinuria is an important clinical marker for predicting the deterioration of renal function in patients. It has been reported that calcium antagonists are expected to reduce urinary protein. Recently, some authors have raised objections that these drugs may cause renal autonomic dysfunction and near-bulb overload And other adverse reactions and increased kidney damage. Accordingly, this article summarizes the recent years of calcium antagonist for the treatment of proteinuric kidney many perspectives for reference.
其他文献